Clinical trials: Dapagliflozin
Aging
SGLT2 Inhibition in Older Obese Adults With Pre-diabetes
Inhibitors of the sodium-glucose co-transporter (SGLT2) are FDA-approved for the treatment of type 2 diabetes (T2DM). Their mechanism of action involves lowering of blood glucose concentration secondary to increased glucose…
- Trial name
- SGLT2i (NCT04401904)
- Testing
- Dapagliflozin 10 mg, Nutritional counseling
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Bioequivalence, Fixed Dose Combination Tablets
A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects
This is a bioequivalence study to compare 2 fixed-dose combination tablets of dapagliflozin/metformin XR manufactured at 2 different plants in healthy subjects under fasting and fed conditions
- Conditions
- Bioequivalence, Fixed Dose Combination Tablets, Healthy Male and Female Subjects
- Trial name
- NCT02637037
- Testing
- dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon), dapagliflozin/metformin XR 5/500 mg reference drug (Humacao), dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon)
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Bioequivalence Study Coadministered to Healthy Subjects in the Fasted State
The purpose of this study is to demonstrate bioequivalence of coadministered drugs on healthy subjects.
- Trial name
- NCT02223065
- Testing
- Saxagliptin, Dapagliflozin
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Polycystic Ovary Syndrome, Obesity
EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)
This is a randomized, single-blind, parallel 5 treatment group 24-week trial designed to directly compare the therapeutic effects of exenatide once weekly (EQW), dapagliflozin (DAPA), EQW plus DAPA, combined DAPA/metformin…
- Trial name
- NCT02635386
- Testing
- Exenatide once weekly (EQW ), Dapagliflozin (DAPA), EQW plus DAPA
- Where
- United States
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Woman's
Diabetes Mellitus, Type 2
An Open-label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Dapagliflozin + Metformin, 10 mg + 1000 mg Versus the Combined Use of Forxiga™, 10 mg and Two Glucophage® Long, ER Tablets, 500 mg Co-administered to Healthy Volunteers Under Standard Fed Conditions
The aim of this study is to demonstrate bioequivalence of fixed dose combination Dapagliflozin + Metformin modified -release, film-coated tablets, 10 mg + 1000 mg, (AstraZeneca AB, Sweden) versus Forxiga™ (Dapagliflozin)…
- Trial name
- NCT02722239
- Testing
- Xigduo XR, Metformin ER (Glucophage® long), Dapagliflozin (Forxiga)
- Where
- Russia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Physical Activity
Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Exercise is frequently prescribed as a favorable lifestyle intervention to prevent/reverse type 2 diabetes. It is also prescribed in addition to concurrent pharmacological treatment, such as metformin.
- Trial name
- NCT02371187
- Testing
- Dapagliflozin
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Christopher Bell
Diabetes Prevention in Women After GDM Who Are at High-risk
Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women
Women with a history of gestational diabetes (GDM) are at substantially increased risk of type 2 diabetes mellitus (T2DM). Compared with the general population, these women are more likely to be overweight or obese.
- Trial name
- DAPA-GDM (NCT02338193)
- Testing
- DAPA/MET XR, DAPA, MET XR
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Woman's
Diabetes Mellitus, Type 2
Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects
Researchers hope to determine the organ (liver and/or kidney) responsible for the increase in endogenous glucose production (EGP) following the induction of glucosuria (when glucose is excreted in detectable amounts in the urine)…
- Trial name
- NCT02981966
- Testing
- Dapagliflozin
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Weight Loss
Does Dapagliflozin Promote Favorable Health Benefits That Are Independent Of Weight Loss?
Th mechanism of action of dapagliflozin is via sodium-glucose co-transporter 2 (SGLT2) inhibition. Sodium-glucose co-transporter 2 inhibition is associated with moderate weight (fat) loss, in addition to other health benefits…
- Trial name
- NCT02520518
- Testing
- Dapagliflozin, Weight maintenance, Ad libitum dietary intake
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Christopher Bell
Diabetes Mellitus, Type 2
Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria
Research Design/Plan: After screening, each subject will receive 1 measurements of Endogenous Glucose Production [EGP] with prime-continuous Infusion of 3-3H-glucose.
- Trial name
- NCT03331289
- Testing
- Exenatide, Dapagliflozin, Exenatide and Dapagliflozin
- Where
- United States
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Platelet Dysfunction
The Effect of Dapagliflozin on Platelet Function testinG Profiles in Diabetic PatiEnts.
Sodium GLucose Transport 2 inhibitors (SGLT2I), including dapagliflozin, reduce the likelihood of hospitalization for heart failure and death in persons with type 2 diabetes, of which the mechanism has not been fully elucidated.
- Trial name
- EDGE (NCT04400760)
- Testing
- DAPA Tx
- Where
- Trinidad and Tobago
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- The University of The West Indies
Type 2 Diabetes Mellitus
Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants
The purpose of this study is to evaluate whether the pharmacokinetics (body concentrations/metabolism of the drug) of Saxagliptin and Dapagliflozin are affected when they are administered together
- Trial name
- NCT01662999
- Testing
- Saxagliptin, Dapagliflozin
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration
The investigators propose to treat newly diagnosed, hyperfiltering T2DM patients with or without microalbuminuria with dapagliflozin or metformin for 4 months.
- Trial name
- Hyper (NCT02911792)
- Testing
- Dapagliflozin, Metformin, Glipizide 5 MG
- Where
- 2 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Weight Loss
Does Dapagliflozin Provide Additional Health Benefits To Dietary Counseling For Weight Loss?
Dapagliflozin is a medicine to treat diabetes. Its mechanism of action is via sodium-glucose co-transporter 2 (SGLT2) inhibition.
- Trial name
- NCT03180489
- Testing
- Dapagliflozin Tablet
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Christopher Bell